Aptevo Therapeutics (APVO) Non-Current Assets (2015 - 2026)
Aptevo Therapeutics (APVO) posted Non-Current Assets of $3.9 million for Q1 2026, down 4.74% sequentially from $4.1 million in Q4 2025, and down 17.25% YoY from $4.7 million in Q1 2025.
Aptevo Therapeutics (APVO) Non-Current Assets (2015 - 2026) Analysis & Trends
Aptevo Therapeutics has reported Non-Current Assets for 12 years, with the latest figure at $3.9 million in Q1 2026.
- Quarterly Non-Current Assets fell 17.25% year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.9 million (down 16.0% YoY) and the FY2025 annual result came in at $4.1 million, down 16.61% from the prior year.
- Non-Current Assets fell to $3.9 million in Q1 2026 per APVO's latest filing, from $4.1 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $7.4 million in Q2 2022 and troughed at $3.5 million in Q1 2022.
- A 5-year average of $5.4 million and a median of $5.3 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets sank 40.5% in 2022, then surged 84.62% in 2023.
- Over 5 years, Non-Current Assets stood at $6.8 million in 2022, then slipped by 14.62% to $5.8 million in 2023, then retreated by 14.61% to $4.9 million in 2024, then declined by 16.61% to $4.1 million in 2025, then fell by 4.74% to $3.9 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $3.9 million, $4.1 million, and $4.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Aptevo Therapeutics | 3.18 Mn | -6.61 Mn | - | 3.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.72 Mn |
| Mar 31, 2026 | 3.92 Mn |
| Dec 31, 2025 | 4.11 Mn |
| Sep 30, 2025 | 4.35 Mn |
| Jun 30, 2025 | 4.54 Mn |
| Mar 31, 2025 | 4.74 Mn |
| Dec 31, 2024 | 4.93 Mn |
| Sep 30, 2024 | 5.13 Mn |
| Jun 30, 2024 | 5.34 Mn |
| Mar 31, 2024 | 5.56 Mn |
| Dec 31, 2023 | 5.78 Mn |
| Sep 30, 2023 | 6.00 Mn |
| Jun 30, 2023 | 6.23 Mn |
| Mar 31, 2023 | 6.48 Mn |
| Dec 31, 2022 | 6.77 Mn |
| Sep 30, 2022 | 7.08 Mn |
| Jun 30, 2022 | 7.40 Mn |
| Mar 31, 2022 | 3.51 Mn |
| Dec 31, 2021 | 4.03 Mn |
| Sep 30, 2021 | 5.13 Mn |